Patrick is the managing editor of PharmaBoardroom
India faces a significant diabetes burden, with some observers even labelling the country ‘The Diabetes Capital of the World’. Around 101.4 million adults, or 11 percent of the Indian population,…
BeiGene may not be a profitable business quite yet, but the Chinese biotech has two top oncology products and saw its sales soar to USD 2.2 billion in 2023. Having…
Some of the biggest stories coming out of Japanese pharma, including Takeda’s USD 2.2 billion Alzheimer’s deal with AC Immune and its plans to restructure; the continuing probe into deaths…
Environmental, Social, and Governance (ESG) concerns have grown in global importance in the last few years due to several factors, including increased awareness of and demand for sustainable investing, the…
In a move to address medicine shortages Mexico’s outgoing president Andrés Manuel López Obrador last year launched a Super Pharmacy, or “Megafarmacia del Bienestar,” dubbed the largest medicine stockpile n…
Throughout his long career, John-Arne Rottingen has gathered experience across multiple domains from discovery research to public health and diplomacy that led him to become the founding CEO of the…
Global pharma has been stepping up M&A activity in Asia while also looking to access Asian markets through local partners and tap into the region’s huge growth potential. As a…
A roundup of some of the biggest stories from South Korean healthcare and pharma, including the government’s continuing standoff with doctors over medical reform plans; Merck’s plans for a new…
In the latest government-driven initiative to tackle drug prices in the US after the Inflation Reduction Act (IRA), California plans to cut drug prices by buying opioid overdose reversal drug…
Chinese player Legend Biotech reached a new turning point last month when its Johnson & Johnson-partnered Carvykti became the first BCMA-targeted CAR-T cell therapy to be approved by the FDA…
The biggest stories from French healthcare and pharma, including AstraZeneca’s acquisition of Amolyt Pharma; protests over Sanofi layoffs; Pierre Fabre’s purchase of Kinnate Biopharma’s experimental pan-RAF inhibitor, and French biotech…
While international pharma has long been present in Saudi Arabia, the ambitious goals outlined in the country’s Vision 2030 economic transformation plan have encouraged companies to reinforce their commitment to…
See our Cookie Privacy Policy Here
